10 January 2020
: Case report
Diagnostic Challenges and Treatment Options for Cutaneous T Cell Pseudolymphoma: A Case Study with Rituximab Treatment
Mistake in diagnosis, Diagnostic / therapeutic accidents, Rare disease
Dārta Balode12ABEF*, Ludmila Beļajeva2B, Vanessa Ruesseler3BE, Alexander Quaas3B, Sandra Lejniece12ABDEDOI: 10.12659/AJCR.919616
Am J Case Rep 2020; 21:e919616
Abstract
BACKGROUND: Pseudolymphoma is a rare disorder that can mimic lymphoma both clinically and histologically. It usually affects middle-aged females. Since pseudolymphoma is a rare disorder not only is diagnosing the condition difficult, but there is also a lack of standardized treatment guidelines. In the literature, anti-CD20 monoclonal antibody rituximab is described as an effective treatment option.
CASE REPORT: 46-year-old female fell ill suddenly with swelling and enlargement of her chin. Multiple skin biopsies were done, which were re-evaluated multiple times as well. Each ended with a new diagnosis for the patient. Finally, in the last revision of biopsy material, pseudolymphoma was confirmed. The patient received multiple courses of corticosteroid treatments – locally and systemically – without long lasting effect. After diagnosis of pseudolymphoma, the patient was started on intravenous rituximab and this treatment was effective.
CONCLUSIONS: Cutaneous pseudolymphoma is a diagnostic challenge. Rituximab is a treatment option for refractory pseudolymphoma. Since there are no treatment guidelines for pseudolymphoma, more clinical studies are needed to establish best treatment options for these patients. Therefore, each reported clinical case is important.
Keywords: Genes, T-Cell Receptor, Pathology, Pseudolymphoma, Antibodies, Monoclonal, Biopsy, Chin, Diagnosis, Differential, Diagnostic Errors, Lymphoma, T-Cell, Cutaneous, Middle Aged, Rare Diseases, rituximab, Skin Diseases
SARS-CoV-2/COVID-19
30 June 2022 : Editorial
Med Sci Monit In Press; DOI: 10.12659/MSM.937676
29 June 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936896
16 June 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936498
13 June 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936889
In Press
30 Jun 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.937061
30 Jun 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936896
30 Jun 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936967
29 Jun 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936313
Most Viewed Current Articles
23 Feb 2022 : Case report
DOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250
17 Feb 2022 : Case report
DOI :10.12659/AJCR.934399
Am J Case Rep 2022; 23:e934399
06 Dec 2021 : Case report
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
09 Feb 2022 : Case report
DOI :10.12659/AJCR.934744
Am J Case Rep 2022; 23:e934744